Citations

Clear

4207 citation(s) found for "Yu, Chen".

Rising maternal circulating GH during murine pregnancy suggests placental regulation
Huang, Lili , Sim, Pamela Su-Lin, Roberts, Claire T. , Velhuis, Johannes D, Chen, Chen , Gatford, Kathryn L. , Mühlhäusler, Beverly Sara , Chen, C

Mayo Clinic

Endocrine Connections | April 12, 2017 | Volume: 6 | Issue: 4 | Pages: 260-266

10.1530/ec-17-0032 | PMID 28404685 Get It

Placenta-derived hormones including growth hormone (GH) in humans contribute to maternal adaptation to pregnancy, and intermittent maternal GH administration increases foetal growth in several species. Both patterns and abundance of circulating GH are important for its activity, but their changes during pregnancy have only been reported in humans and rats. The aim of the present study was to characterise circulating profiles and secretory characteristics of GH in non-pregnant female mice and throughout murine pregnancy. Circulating GH concentrations were measured in whole blood (2 μL) collected every 10 min for 6 h in non-pregnant diestrus female C57Bl/6J mice ( n = 9), and pregnant females at day 8.5–9.5 (early pregnancy, n = 8), day 12.5–13.5 (mid-pregnancy, n = 7) and day 17.5 after mating (late pregnancy, n = 7). Kinetics and secretory patterns of GH secretion were determined by deconvolution analysis, while orderliness and regularity of serial GH concentrations were calculated by approximate entropy analysis. Circulating GH was pulsatile in all groups. Mean circulating GH and total and basal GH secretion rates increased markedly from early to mid-pregnancy, and then remained elevated. Pulse frequency and pulsatile GH secretion rate were similar between groups. The irregularity of GH pulses was higher in all pregnant groups than that in non-pregnant mice. Increased circulating GH in murine pregnancy is consistent with an important role for this hormone in maternal adaptation to pregnancy and placental development. The timing of increased basal secretion from mid-pregnancy, concurrent with the formation of the chorioallantoic placenta and initiation of maternal blood flow through it, suggests regulation of pituitary secretion by placenta-derived factors.
Neovascularization Failure of an Interposed Free Intestinal Colon Flap 10 Years after Esophageal Reconstruction
Manrique, Oscar J. , Ciudad, Pedro , Chen, Shih‐Heng , Chen, Hung‐Chi

Mayo Clinic

Journal of Reconstructive Microsurgery Open | April 10, 2017 | Volume: 02 | Issue: 01 | Pages: e35-e36

10.1055/s-0037-1601850 Get It

Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518
Yao, James C. , Guthrie, Katherine A. , Moran, César A. , Kulke, Matthew H. , Chan, Jennifer A. , LoConte, Noelle K. , Wolin, Edward M. , Mattar, Bassam, McDonough, Shannon, Blanke, Charles D. , Höchster, Howard S. , Moran, Cesar, LoConte, Noelle, McWilliams, Robert R. , Chen, Helen, Strosberg, Jonathan , Chen, Helen , LoConte, Noelle

Mayo Clinic

Journal of Clinical Oncology | April 6, 2017 | Volume: 35 | Issue: 15 | Pages: 1695-1703

10.1200/jco.2016.70.4072 | PMID 28384065 Get It

Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group system, enrolled patients with advanced grades 1 and 2 NETs with progressive disease or other poor prognostic features. Patients were randomly assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-α-2b three times per week. The primary end point was centrally assessed PFS. This trial is registered with ClinicalTrials.gov as NCT00569127. Results A total of 427 patients was enrolled, of whom 214 were allocated to bevacizumab and 213 to IFN-α-2b. The median PFS by central review was 16.6 months (95% CI, 12.9 to 19.6 months) in the bevacizumab arm and was 15.4 months (95% CI, 9.6 to 18.6 months) in the IFN arm (hazard ratio [HR], 0.93; 95% CI, 0.73 to 1.18; P = .55). By site review, the median PFS times were 15.4 months (95% CI, 12.6 to 17.2 months) for bevacizumab and 10.6 months (95% CI, 8.5 to 14.4 months) for interferon (HR, 0.90; 95% CI, 0.72 to 1.12; P = .33). Time to treatment failure was longer with bevacizumab than with IFN (HR, 0.72; 95% CI, 0.58 to 0.89; P = .003). Confirmed radiologic response rates were 12% (95% CI, 8% to 18%) for bevacizumab and 4% (95% CI, 2% to 8%) for IFN. Common adverse events with bevacizumab and octreotide included hypertension (32%), proteinuria (9%), and fatigue (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%). Conclusion No significant differences in PFS were observed between the bevacizumab and IFN arms, which suggests that these agents have similar antitumor activity among patients with advanced NETs.
Quality of life (QOL) and pain in advanced stage prostate cancer: impact of missing data on evaluating palliation in SWOG 9916
Moinpour, Carol M. , Vinson, Liara, Lara, Primo N. , Taplin, Mary‐Ellen , Burch, Patrick, Petrylak, Daniel P. , Berry, Donna Lynn , Jiang, Chen , Lanier, Stephen M. , Crawford, Emily D.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 4579-4579

10.1200/jco.2004.22.90140.4579 Get It

Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes
Earp, Madalene A. , Li, Qian , Cunningham, Julie M. , Natanzon, Yanina , Kalli, Kimberly R., Hou, Xiaonan , Weroha, S. John , Haluska, Paul , Lawrenson, Kate , Gayther, Simon A. , Goode, Ellen L. , Winham, Stacey J. , Raghavan, Rama , Dai, Junqiang , Wang, Chen , Fridley, Brooke L. , Lawrenson, Kate

Mayo Clinic

Oncotarget | April 1, 2017 | Volume: 8 | Issue: 29 | Pages: 46891-46899

10.18632/oncotarget.16781 | PMID 28423358 Get It

EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression
Wang, Xiangling , Fang, Juemin, Xue, Junli , Xiong, Xunhao, Huang, Yan , Hu, Jinghua , Ling, Kun , Chen, Chunhua

Mayo Clinic

Oncotarget | March 31, 2017 | Volume: 8 | Issue: 26 | Pages: 42621-42637

10.18632/oncotarget.16730 | PMID 28388589 Get It

Evaluation of a projection-domain lung nodule insertion technique in thoracic computed tomography
Yu, Lifeng , Chen, Baiyu , Koo, Chi Wan , Takahashi, Edwin A. , Levin, David L. , Viers, Lyndsay D., Vincent-Sheldon, Stephanie, Ma, Chi , Kuzo, Ronald S. , Vincent-Sheldon, Stephanie A, Ma, Chi , Chen, Baiyu , Leng, Shuai , Leng, Shuai , Takahashi, Edwin A

Mayo Clinic

Journal of Medical Imaging | March 31, 2017 | Volume: 4 | Issue: 1 | Pages: 013510

10.1117/1.jmi.4.1.013510 | PMID 28401176 Get It

Oxidative Stress-Induced Afterdepolarizations and Protein Kinase C Signaling
Fei, Yu-Dong, Hou, Jian-Wen, Guo, Kai , Chen, Xiao-Meng, Chen, Yi-He , Wang, Qian , Xu, Xiao-Lei, Wang, Yue-Peng, Li, Yi‐Gang , Fei, Yudong, Li, Wei , Wang, Yue‐Peng

Mayo Clinic

International Journal of Molecular Sciences | March 30, 2017 | Volume: 18 | Issue: 4 | Pages: 688

10.3390/ijms18040688 | PMID 28358314 Get It

Background: Hydrogen peroxide (H2O2)-induced oxidative stress has been demonstrated to induce afterdepolarizations and triggered activities in isolated myocytes, but the underlying mechanisms remain not fully understood. We aimed to explore whether protein kinase C (PKC) activation plays an important role in oxidative stress-induced afterdepolarizations. Methods: Action potentials and ion currents of isolated rabbit cardiomyocytes were recorded using the patch clamp technique. H2O2 (1 mM) was perfused to induce oxidative stress and the specific classical PKC inhibitor, Gö 6983 (1 μM), was applied to test the involvement of PKC. Results: H2O2 perfusion prolonged the action potential duration and induced afterdepolarizations. Pretreatment with Gö 6983 prevented the emergence of H2O2-induced afterdepolarizations. Additional application of Gö 6983 with H2O2 effectively suppressed H2O2-induced afterdepolarizations. H2O2 increased the late sodium current (INa,L) (n = 7, p < 0.01) and the L-type calcium current (ICa,L) (n = 5, p < 0.01), which were significantly reversed by Gö 6983 (p < 0.01). H2O2 also increased the transient outward potassium current (Ito) (n = 6, p < 0.05). However, Gö 6983 showed little effect on H2O2-induced enhancement of Ito. Conclusions: H2O2 induced afterdepolarizations via the activation of PKC and the enhancement of ICa,L and INa,L. These results provide evidence of a link between oxidative stress, PKC activation and afterdepolarizations.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: Ca
Somlo, George, Frankel, Paul , Cynthia, X. , García, Agustin A. , Cigler, Tessa, Cream, Leah, Harvey, Harold A., Sparano, Joseph A. , Nanda, Rita , Chew, Helen K. , Moynihan, Timothy J. , Hurria, Arti , Mortimer, Joanne , Sand, Sharon , Herzog, Josef , Tongeren, Lily R. Van, Ferry‐Galow, Katherine V., Chen, Alice P. , Ruel, Christopher , Newman, Edward M. , Gandara, David R. , Weitzel, Jeffrey N. , Arun, Banu , Vahdat, Linda T. , Goetz, Matthew P. , Beumer, Jan Hendrik , Piekarz, Richard , Weitzel, Jeffrey N , Sparano, Joseph A , Gandara, David

Mayo Clinic

Clinical Cancer Research | March 29, 2017 | Volume: 23 | Issue: 15 | Pages: 4066-4076

10.1158/1078-0432.ccr-16-2714 | PMID 28356425 Get It

Abstract Purpose: We aimed to establish the MTD of the poly (ADP-ribose) (PAR) polymerase inhibitor, veliparib, in combination with carboplatin in germline BRCA1- and BRCA2- (BRCA)-associated metastatic breast cancer (MBC), to assess the efficacy of single-agent veliparib, and of the combination treatment after progression, and to correlate PAR levels with clinical outcome. Experimental Design: Phase I patients received carboplatin (AUC of 5–6, every 21 days), with escalating doses (50-20 mg) of oral twice-daily (BID) veliparib. In a companion phase II trial, patients received single-agent veliparib (400 mg BID), and upon progression, received the combination at MTD. Peripheral blood mononuclear cell PAR and serum veliparib levels were assessed and correlated with outcome. Results: Twenty-seven phase I trial patients were evaluable. Dose-limiting toxicities were nausea, dehydration, and thrombocytopenia [MTD: veliparib 150 mg po BID and carboplatin (AUC of 5)]. Response rate (RR) was 56%; 3 patients remain in complete response (CR) beyond 3 years. Progression-free survival (PFS) and overall survival (OS) were 8.7 and 18.8 months. The PFS and OS were 5.2 and 14.5 months in the 44 patients in the phase II trial, with a 14% RR in BRCA1 (n = 22) and 36% in BRCA2 (n = 22). One of 30 patients responded to the combination therapy after progression on veliparib. Higher baseline PAR was associated with clinical benefit. Conclusions: Safety and efficacy are encouraging with veliparib alone and in combination with carboplatin in BRCA-associated MBC. Lasting CRs were observed when the combination was administered first in the phase I trial. Further investigation of PAR level association with clinical outcomes is warranted. Clin Cancer Res; 23(15); 4066–76. ©2017 AACR.
Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial.
Jarrard, David F. , Liu, Glenn , Eisenberger, Mario A. , Wong, Yu‐Ning, Hahn, Noah M. , Cooney, Matthew M. , Shevrin, Daniel H. , García, Jorge A. , DiPaola, Robert S. , Chen, Yu‐Hui , Carducci, Michael A. , Kohli, Manish , Dreicer, Robert , Vogelzang, Nicholas J. , Picus, Joel , Hussain, Maha , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 181-181

10.1200/jco.2017.35.6_suppl.181 Get It

181 Background: To evaluate whether metformin (Met) a widely-used, nontoxic oral antidiabetic drug with putative anticancer properties leads to improvements in prostate cancer (PC) outcomes in the CHAARTED trial. Methods: In the CHAARTED database where metformin use at baseline was recorded prospectively, we identified patients with metastatic PC who underwent either ADT alone or ADT and docetaxel (D) chemotherapy. Cox proportional hazards models were used to determine the effect of Metformin on outcomes. Results: A total of 788 patients (median age, 63 y) had complete data after randomization. Comparison of ADT+D+Met (n = 39) to ADT+D (n = 357) and ADT+Met (n = 29) to ADT alone (n = 363) revealed similar clinicopathologic characteristics. Cause of death was PC in 13(81%) of ADT+D+Met, 72(85%) ADT+D, 9(82%) ADT+Met and 105(84%) ADT alone groups. See table for PC outcomes and overall survival by metformin use. Cox regression analysis for overall survival stratified by stratification factors at randomization demonstrates Met use was associated with a trend for worse overall survival (HR 1.47 95%CI: [0.95,2.26], p = 0.08) with adjustment for treatment arm and prior local therapy. In contrast, ADT+D use (HR 0.62; 95%CI: [0.47,0.81]) and prior local therapy with surgery or radiation (HR 0.56; 95% CI: [0.38, 0.82]) were associated with improved survival. Conclusions: In this study, baseline metformin did not improve PC outcomes. Partial support and drug supply by Sanofi. Clinical trial information: NCT00309985. [Table: see text]